The goal of this observational study on chimeric antigen receptor T-cell therapy is to monitor the feasibility, efficacy, toxicity and biomarkers in a real life setting.
Partecipants will be asked to agree to their clinical data collection and to partecipate to the optional biological study that aims to evaluate biomarkers of toxicity and response (clinical characteristics, cytokine profile, cellcomposition and type of the CAR-T cell product, lymphoma genomics). The study will evaluate even the disease response according to lugano criteria by PET and CT in routine clinical activity.
Patients with diagnosis of DLCBL, PMBCL, MCL and FL eligible for CAR-T treatment with commercialy available products in Italy.
Not applicable
Paolo Corradini
Lead sponsor
Fondazione IRCCS Istituto Nazionale dei Tumori, Milano
Sponsor institution
Annalisa Chiappella
Collaborator
Cristiana Carniti
Collaborator
Anna Dodero
Collaborator